Nichi-Iko Pharmaceutical Co Ltd (4541):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nichi-Iko Pharmaceutical Co Ltd (4541) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5167
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nichi-Iko Pharmaceutical Co Ltd (Nichi-Iko) is a manufacturer of generic products. The company eripheral nervous system medicines. The company offers products such as alacepril tablets, aluminum hydroxide gel, aranidipine capsules, bacampicillin hydrochloride tablets, barium sulfate, betahistine mesilate tablets, calcium gluconate hydrate powder, candesartan cilexetil tablets and diltiazem hydrochloride table, among others. Its products are used for treatments of circulatory, digestive, respiratory, central and peripheral nervous systems. Nichi-Iko offers manufacturing, sales, distribution, export, import and related activities for various types of pharmaceuticals. The company operates in Sapporo, Sendai, Kanto, Tokai-Hokuriku, Osaka, Hiroshima, Fukuoka, and others. Nichi-Iko is headquartered in Toyama, Japan.

Nichi-Iko Pharmaceutical Co Ltd (4541) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nichi-Iko Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 12
Nichi-Iko Pharma Acquires Pharmaceutical Manufacturing Business from Astellas Pharma Tech 13
Partnerships 14
Lupin and Nichi-Iko Enter into Partnership Agreement 14
Eisai Enters into Agreement with Nichi-Iko Pharma 15
Nichi-Iko Pharma Enters Into Co-Marketing Agreement With Biolab 16
Equity Offering 17
Sagent Pharma Completes Public Offering Of Shares For US$75.3 Million 17
Acquisition 19
Nichi-iko Pharma Acquires Sagent Pharma for USD734.2 Million in Tender Offer 19
Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 21
Hong Kong King-Friend Pharmaceutical Acquires 100% Stake in Sagent (China) Pharma From Sagent Pharma 22
Nichi-Iko Pharma Divests 12.6% Stake in Binex for USD50 Million 23
Sagent Pharma Acquires Omega Labs for USD85.3 Million 24
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 26
Sagent Pharma Acquires Remaining 50% JV Stake in Kanghong Sagent from Chengdu Kanghong Pharma for USD25 Million 27
Nichi-Iko Pharma Acquires 69% Stake In Yakuhan Pharma 28
Nichi-Iko Pharmaceutical Co Ltd – Key Competitors 29
Nichi-Iko Pharmaceutical Co Ltd – Key Employees 30
Nichi-Iko Pharmaceutical Co Ltd – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 32
Recent Developments 33
Strategy And Business Planning 33
Apr 17, 2018: Nichi-Iko Pharmaceutical: Announcement of completion of new production facility by Aprogen Biologics 33
Financial Announcements 34
Feb 07, 2018: Nichi-Iko Pharmaceutical Reports Consolidated Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2018 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nichi-Iko Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Nichi-Iko Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 12
Nichi-Iko Pharma Acquires Pharmaceutical Manufacturing Business from Astellas Pharma Tech 13
Lupin and Nichi-Iko Enter into Partnership Agreement 14
Eisai Enters into Agreement with Nichi-Iko Pharma 15
Nichi-Iko Pharma Enters Into Co-Marketing Agreement With Biolab 16
Sagent Pharma Completes Public Offering Of Shares For US$75.3 Million 17
Nichi-iko Pharma Acquires Sagent Pharma for USD734.2 Million in Tender Offer 19
Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 21
Hong Kong King-Friend Pharmaceutical Acquires 100% Stake in Sagent (China) Pharma From Sagent Pharma 22
Nichi-Iko Pharma Divests 12.6% Stake in Binex for USD50 Million 23
Sagent Pharma Acquires Omega Labs for USD85.3 Million 24
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 26
Sagent Pharma Acquires Remaining 50% JV Stake in Kanghong Sagent from Chengdu Kanghong Pharma for USD25 Million 27
Nichi-Iko Pharma Acquires 69% Stake In Yakuhan Pharma 28
Nichi-Iko Pharmaceutical Co Ltd, Key Competitors 29
Nichi-Iko Pharmaceutical Co Ltd, Key Employees 30
Nichi-Iko Pharmaceutical Co Ltd, Other Locations 31
Nichi-Iko Pharmaceutical Co Ltd, Subsidiaries 32
Nichi-Iko Pharmaceutical Co Ltd, Joint Venture 32

List of Figures
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nichi-Iko Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Nichi-Iko Pharmaceutical Co Ltd (4541):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The E. W. Scripps Company:戦略・SWOT・企業財務分析
    The E. W. Scripps Company - Strategy, SWOT and Corporate Finance Report Summary The E. W. Scripps Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Thai Airways International Public Co Ltd:戦略・SWOT・企業財務分析
    Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • China CITIC Bank International Limited:企業の戦略・SWOT・財務情報
    China CITIC Bank International Limited - Strategy, SWOT and Corporate Finance Report Summary China CITIC Bank International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Saia Inc (SAIA):企業の財務・戦略的SWOT分析
    Saia Inc (SAIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Foley Family Wines Limited:企業の戦略・SWOT・財務情報
    Foley Family Wines Limited - Strategy, SWOT and Corporate Finance Report Summary Foley Family Wines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • CitiPower and Powercor:企業の戦略的SWOT分析
    CitiPower and Powercor - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Interstate Hotels & Resorts Inc:企業のM&A・事業提携・投資動向
    Interstate Hotels & Resorts Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Interstate Hotels & Resorts Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Volga Gas plc (VGAS):企業の財務・戦略的SWOT分析
    Summary Volga Gas Plc (Volga Gas) is an oil and gas company that provides oil and gas exploration and production services. The company acquires, produces and develops oil, natural gas deposit properties, and others. It owns and operates oil and gas producing assets in Karpenskiy licence area, Pre-Ca …
  • Arqvia Group Ltd:企業の戦略・SWOT・財務分析
    Arqvia Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Arqvia Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • AMW GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary AMW GmbH (AMW) is a pharmaceutical company that develops and manufactures drug delivery systems for treatment in the areas of oncology, neurology, dermatology and pain. The company designs and develops novel transdermal drug delivery systems, microchip controlled patches and biodegradable su …
  • Standard Chartered Bank Kenya Ltd:企業の戦略・SWOT・財務分析
    Standard Chartered Bank Kenya Ltd - Strategy, SWOT and Corporate Finance Report Summary Standard Chartered Bank Kenya Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Westlake Chemical Corporation:企業の戦略・SWOT・財務情報
    Westlake Chemical Corporation - Strategy, SWOT and Corporate Finance Report Summary Westlake Chemical Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Pear Therapeutics Inc:企業の製品パイプライン分析2018
    Summary Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive …
  • Hunan Fangsheng Pharmaceutical Co Ltd (603998):製薬・医療:M&Aディール及び事業提携情報
    Summary Hunan Fangsheng Pharmaceutical Co Ltd (Fangsheng Pharma) is a research-based comprehensive pharmaceutical enterprise offers research, development, manufacturing and sales of pharmaceuticals. The enterprise’ products include tablets, capsules, granules, oral suspension, powder, suppository, p …
  • Grand Haven Board of Light and Power:企業の戦略的SWOT分析
    Grand Haven Board of Light and Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Sygnis AG (LIO1)-医療機器分野:企業M&A・提携分析
    Summary Sygnis AG (Sygnis), formerly Sygnis Pharma AG is a biopharmaceutical company that develops novel products and tools in fields of molecular biology. The company undertakes development and marketing of new molecular biological technologies for DNA amplification and sequencing. Its products inc …
  • Cemat AS (CEMAT):企業の財務・戦略的SWOT分析
    Cemat AS (CEMAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Yes Bank Limited:戦略・SWOT・企業財務分析
    Yes Bank Limited - Strategy, SWOT and Corporate Finance Report Summary Yes Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Domino’S Pizza Group Plc
    Domino'S Pizza Group Plc - Strategy, SWOT and Corporate Finance Report Summary Domino'S Pizza Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Andritz AG (ANDR):企業の財務・戦略的SWOT分析
    Andritz AG (ANDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆